Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

RCT (n=706) found that ixazomib improved progression free survival vs placebo (17.4 vs 9.4 months, HR for progression or death 0.659; 95%CI 0.542 to 0.801) and 36.6% vs 23.2% of patients had grade ≥ 3 treatment-emergent adverse events respectively.

Journal of Clinical Oncology